NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI) physicians authored four abstracts accepted for presentation at the ASCO 2012 Gastrointestinal Cancers Symposium, which runs from Jan. 19-21 in San Francisco, CA.
“The incorporation of new agents, particularly targeted therapies, in the treatment of gastrointestinal cancers continues to improve clinical outcomes for patients,” said Howard A. Burris III, M.D., SCRI’s chief medical officer and executive director, drug development. “We are honored to share results of this important research with the top GI cancer researchers in the world.”
“The incorporation of new agents, particularly targeted therapies, in the treatment of gastrointestinal cancers continues to improve clinical outcomes for patients,” said Howard A. Burris III, M.D., SCRI’s chief medical officer and executive director, drug development. “We are honored to share results of this important research with the top GI cancer researchers in the world.”
